Hypertension Diagnostics (OTCMKTS:HDII) and DexCom (NASDAQ:DXCM) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, risk, institutional ownership and dividends.
Institutional and Insider Ownership
0.0% of Hypertension Diagnostics shares are owned by institutional investors. Comparatively, 96.4% of DexCom shares are owned by institutional investors. 40.0% of Hypertension Diagnostics shares are owned by insiders. Comparatively, 1.8% of DexCom shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
This table compares Hypertension Diagnostics and DexCom’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility and Risk
Hypertension Diagnostics has a beta of -5.28, meaning that its stock price is 628% less volatile than the S&P 500. Comparatively, DexCom has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500.
Valuation and Earnings
This table compares Hypertension Diagnostics and DexCom’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|DexCom||$1.03 billion||13.17||-$127.10 million||$0.30||497.23|
Hypertension Diagnostics has higher earnings, but lower revenue than DexCom.
This is a breakdown of recent ratings for Hypertension Diagnostics and DexCom, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
DexCom has a consensus price target of $151.44, suggesting a potential upside of 1.52%. Given DexCom’s higher possible upside, analysts plainly believe DexCom is more favorable than Hypertension Diagnostics.
DexCom beats Hypertension Diagnostics on 7 of the 9 factors compared between the two stocks.
Hypertension Diagnostics Company Profile
Hypertension Diagnostics, Inc. designs, develops, manufactures, and markets proprietary noninvasive medical devices that detect subtle changes in the elasticity of arteries in the United States and internationally. It offers CVProfilor, which allows a physician to non-invasively assess the elasticity of small and large arteries, of which small artery elasticity is the earliest and sensitive marker of cardiovascular disease. The company offers CVProfilor DO-2020, which provides a patient's arterial elasticity indices used in the assessment for underlying vascular disease; CVProfilor MD-3000 that offers a sensitive and specific guide to the presence of blood vessel disease; and HD/PulseWave CR-2000 research cardiovascular profiling system, which provides researchers and scientists with a non-invasive means to assess arterial elasticity in support of human research in various areas. Its products collect 30 seconds of blood pressure waveform data, perform an analysis of the digitized blood pressure waveforms, and generate a CVProfile report that contains information on blood pressure, heart rate, pulse pressure, body surface area, body mass index, and C1-large and C2-small artery elasticity indices. The company sells its products to primary care physicians, cardiologists, health care professionals, trained medical personnel, research investigators at academic medical research centers, government institutes, cardiovascular specialists, and pharmaceutical firms. It markets its products through a representative organization in the United States. Hypertension Diagnostics, Inc. was founded in 1988 and is based in Minnetonka, Minnesota.
DexCom Company Profile
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop a series of next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Receive News & Ratings for Hypertension Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hypertension Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.